The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. (MDCX) reported that Chief Executive Officer and director Raza Bokhari received equity awards on September 4, 2026. He was granted 500,000 stock options to buy Common Shares at an exercise price of $0.1705 per share, expiring on September 4, 2031. These options are scheduled to vest quarterly in four equal installments over one year. On the same date, he also acquired 2,941,176 Common Shares at $0.1705 per share, all held directly, and no Rule 10b5-1 trading plan is reported.
Medicus Pharma Ltd. (MDCX) filed a prospectus supplement registering 3,245,595 common shares issuable upon exercise of outstanding warrants and updating investors with a new collaboration disclosure. The attached Form 8-K describes a Co-Development and License Agreement under which Pfizer granted Medicus exclusive, worldwide rights to develop and commercialize CD228V, an early clinical-stage antibody-drug conjugate targeting melanotransferrin (CD228). Medicus paid Pfizer a $12.0 million upfront fee, will owe an additional $15.0 million on the first anniversary, and received a $2.0 million Development Funding Payment to support CD228V development. Pfizer remains economically involved through potential development, regulatory and sales milestones that in aggregate exceed $1.0 billion and through low double-digit royalties on annual net sales, while Medicus retains control over development, regulatory and commercialization activities.
Medicus Pharma Ltd. (MDCX) entered into a Co-Development and License Agreement with Pfizer Inc. for PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin (CD228). Medicus receives an exclusive, sublicensable, worldwide license to develop, manufacture and commercialize CD228V and related products for all human diseases.
As consideration, Medicus paid Pfizer a $12.0 million non-refundable upfront payment and must pay an additional $15.0 million on the first anniversary of the effective date. Pfizer paid Medicus a $2.0 million non-refundable Development Funding Payment to be used solely for CD228V development activities. Pfizer is eligible for development, regulatory and sales-based milestone payments that in aggregate exceed $1.0 billion, plus tiered low double-digit royalties on annual Net Sales.
Medicus retains sole authority and bears the costs for development, regulatory approval, manufacturing and commercialization, while Pfizer keeps ownership of the patent rights and an economic interest via milestones, royalties and specified participation in change-of-control, sublicensing or other strategic transactions. Pfizer also holds an option to fund all or part of development from and after the first pivotal trial, subject to a separate definitive agreement.
Medicus Pharma Ltd. is registering 3,245,595 common shares issuable upon exercise of outstanding warrants, each with a $4.64 exercise price and expiring November 15, 2029. Common shares and public warrants trade on Nasdaq as MDCX and MDCXW.
For the quarter ended June 30, 2026, Medicus reported a net loss of $11.7 million, and a six‑month loss of $20.7 million, driven by $20.1 million in operating expenses, including increased R&D for SkinJect and Teverelix. Cash and cash equivalents were $15.2 million with an additional $10.0 million of restricted cash; total assets were $27.1 million and total liabilities $28.8 million, resulting in negative shareholders’ equity of $(1.7) million.
Financing inflows for the first half of 2026 included $22.0 million of secured promissory notes, $12.4 million from an at‑the‑market program, and $4.1 million via a standby equity purchase agreement. Management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital and notes a Nasdaq notice for not meeting the $1.00 minimum bid price requirement.
Medicus Pharma Ltd. reported a larger loss and higher spending for the quarter and six months ended June 30, 2026, while significantly increasing its cash through new debt and equity financings. The company remains a clinical-stage biotech with no product revenue and focuses on its SkinJect microneedle cancer patch and Teverelix programs.
Total assets were $27.1 million, including cash and cash equivalents of $15.2 million and restricted cash of $10.0 million, against total liabilities of $28.8 million, resulting in a shareholders’ deficit of $1.7 million. The six‑month net loss widened to $20.7 million from $11.3 million a year earlier, driven by higher general and administrative expenses of $12.5 million and research and development expenses of $7.6 million, including increased Teverelix trial activity and stock‑based compensation.
Operating cash use was $16.0 million over six months, funded by $32.4 million of financing inflows: $22.0 million in secured promissory notes, $12.4 million from an at‑the‑market program and $4.1 million from a standby equity purchase agreement, partly offset by debenture repayment. Management discloses substantial doubt about the company’s ability to continue as a going concern without further capital and notes a Nasdaq minimum bid‑price deficiency.
Medicus Pharma Ltd. files a prospectus supplement amending its Form S-1 to register 3,245,595 Common Shares issuable upon exercise of outstanding warrants. The supplement incorporates a Form 8-K dated June 3, 2026 and updates offering and corporate information.
The Public Warrants have an exercise price of $4.64 and an expiration date of November 15, 2029. The prospectus notes last reported sales prices on June 3, 2026 of the common shares at $0.3576 and the Public Warrants at $0.50. The attached Form 8-K reports shareholders ratified KPMG, elected nine directors, and approved a potential share consolidation of up to 50 pre-consolidation for 1 post-consolidation share.
Medicus Pharma Ltd. held its 2026 Annual General and Special Meeting of Shareholders on June 3, 2026. Shareholders ratified the appointment of KPMG LLP as independent auditor for the 2026 fiscal year, with 28,308,860 votes for and 756,378 votes withheld.
All nine director nominees were elected, each receiving about 15.1 million votes for and 13.5 million broker non-votes. Shareholders also approved a special resolution authorizing the board to implement a consolidation of the company’s common shares at a ratio of up to 50 pre-consolidation shares for each post-consolidation share, if the board determines such a step is necessary or desirable.
Medicus Pharma Ltd. Chief Operating Officer Andrew Alasdair Smith received a grant of stock options covering 200,000 common shares on June 3, 2026. The options have an exercise price of $0.36 per share, vest quarterly in four equal installments over one year, and expire on June 3, 2031. Following this grant, he holds 200,000 options directly.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. According to the footnote, the award vests quarterly in four equal installments over one year, meaning the director earns 12,500 options every quarter until fully vested. Following this grant, she holds 50,000 stock options directly, providing equity-based compensation linked to the company’s future share performance.
Medicus Pharma Ltd. director Ajay Raju received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and were granted as a compensation award at no upfront cost. They are scheduled to vest quarterly in four equal installments over one year, giving Raju the right, once vested, to buy Medicus Pharma common shares at the fixed exercise price until the options expire in 2031.